EP3843721A4 - Ophthalmic compositions and methods of use - Google Patents

Ophthalmic compositions and methods of use Download PDF

Info

Publication number
EP3843721A4
EP3843721A4 EP19856338.9A EP19856338A EP3843721A4 EP 3843721 A4 EP3843721 A4 EP 3843721A4 EP 19856338 A EP19856338 A EP 19856338A EP 3843721 A4 EP3843721 A4 EP 3843721A4
Authority
EP
European Patent Office
Prior art keywords
methods
ophthalmic compositions
ophthalmic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19856338.9A
Other languages
German (de)
French (fr)
Other versions
EP3843721A1 (en
Inventor
Rasappa Arumugham
Arun UPADHYAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocugen Inc
Original Assignee
Ocugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/116,872 external-priority patent/US20190008920A1/en
Application filed by Ocugen Inc filed Critical Ocugen Inc
Publication of EP3843721A1 publication Critical patent/EP3843721A1/en
Publication of EP3843721A4 publication Critical patent/EP3843721A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19856338.9A 2018-08-29 2019-08-29 Ophthalmic compositions and methods of use Withdrawn EP3843721A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/116,872 US20190008920A1 (en) 2017-05-19 2018-08-29 Ophthalmic compositions and methods of use
PCT/US2019/048721 WO2020047197A1 (en) 2018-08-29 2019-08-29 Ophthalmic compositions and methods of use

Publications (2)

Publication Number Publication Date
EP3843721A1 EP3843721A1 (en) 2021-07-07
EP3843721A4 true EP3843721A4 (en) 2022-10-12

Family

ID=69644699

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19856338.9A Withdrawn EP3843721A4 (en) 2018-08-29 2019-08-29 Ophthalmic compositions and methods of use

Country Status (4)

Country Link
EP (1) EP3843721A4 (en)
CN (1) CN111212642A (en)
CA (1) CA3115664A1 (en)
WO (1) WO2020047197A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024042550A1 (en) * 2022-08-25 2024-02-29 Sentiss Pharma Private Limited Ophthalmic combination composition

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225217A1 (en) * 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
EP1827373B1 (en) * 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
AU2012351948A1 (en) * 2011-12-16 2014-07-10 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer
US9034830B2 (en) * 2009-10-30 2015-05-19 Intratus, Inc. Methods and compositions for sustained delivery of drugs
US9597328B2 (en) * 2015-02-24 2017-03-21 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US20170304316A1 (en) * 2014-10-20 2017-10-26 Sentiss Pharma Private Limited Ophthalmic Solution
US20180055943A1 (en) * 2016-08-23 2018-03-01 Ira Jason Salzman Ophthalmic lubricating spray
US20180153885A1 (en) * 2015-02-24 2018-06-07 The Board Of Trustees Of The University Of Illinois Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders
WO2018139991A1 (en) * 2017-01-24 2018-08-02 Macregen, Inc. Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics
US20180221278A1 (en) * 2015-02-24 2018-08-09 Ocugen, Inc. Prsustained release opthalmic formuation and methods for using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2094688B1 (en) * 1994-08-08 1997-08-01 Cusi Lab MANOEMULSION OF THE TYPE OF OIL IN WATER, USEFUL AS AN OPHTHALMIC VEHICLE AND PROCEDURE FOR ITS PREPARATION.
WO2001041806A1 (en) * 1999-12-07 2001-06-14 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
MX2007010025A (en) * 2007-08-17 2009-02-25 Arturo Jimenez Bayardo Pharmaceutical composition for treatment of ocular hypertension.
EP2664329A1 (en) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmological vehicle system
CN102895245A (en) * 2012-10-30 2013-01-30 河南牧翔动物药业有限公司 Compound trimethoprim and doxycycline hydrochloride nanoemulsion preparation and preparation method thereof
WO2016060917A2 (en) * 2014-10-15 2016-04-21 Rapid Pathogen Screening, Inc. Formulations for histatin therapeutics
MX2019003623A (en) * 2016-09-28 2019-09-23 Medicon Pharmaceuticals Inc Compositions and methods for treating ophthalmic conditions.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1827373B1 (en) * 2004-11-09 2008-12-03 Novagali Pharma SA Ophthalmic emulsions containing prostaglandins
US20070225217A1 (en) * 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US9034830B2 (en) * 2009-10-30 2015-05-19 Intratus, Inc. Methods and compositions for sustained delivery of drugs
AU2012351948A1 (en) * 2011-12-16 2014-07-10 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer
US20170304316A1 (en) * 2014-10-20 2017-10-26 Sentiss Pharma Private Limited Ophthalmic Solution
US9597328B2 (en) * 2015-02-24 2017-03-21 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US20180153885A1 (en) * 2015-02-24 2018-06-07 The Board Of Trustees Of The University Of Illinois Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders
US20180221278A1 (en) * 2015-02-24 2018-08-09 Ocugen, Inc. Prsustained release opthalmic formuation and methods for using the same
US20180055943A1 (en) * 2016-08-23 2018-03-01 Ira Jason Salzman Ophthalmic lubricating spray
WO2018139991A1 (en) * 2017-01-24 2018-08-02 Macregen, Inc. Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020047197A1 *

Also Published As

Publication number Publication date
CN111212642A (en) 2020-05-29
EP3843721A1 (en) 2021-07-07
WO2020047197A1 (en) 2020-03-05
CA3115664A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
EP3704239A4 (en) Casz compositions and methods of use
EP3775203A4 (en) Oligonucleotide compositions and methods of use thereof
EP3790596A4 (en) Oligonucleotide compositions and methods of use thereof
EP3624773A4 (en) Ophthalmic compositions and methods of use
EP3704254A4 (en) Cas12c compositions and methods of use
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
EP3595653A4 (en) Compositions of plinabulin and use thereof
EP3691677A4 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
EP3600372A4 (en) Synthekine compositions and methods of use
EP3893917A4 (en) Il-15 compositions and methods of use thereof
EP3265096A4 (en) Ophthalmic compositions and methods of use therefor
EP3829307A4 (en) Bismuth-thiol compositions and methods of use
EP3802553A4 (en) Silicon-containing compositions and their methods of use
EP3856214A4 (en) Microbial compositions and methods of use
EP3886853A4 (en) Diarylhydantoin compounds and methods of use thereof
EP3740576A4 (en) Therapeutic compositions and methods of making and using the same
EP3863630A4 (en) Compositions and methods for the treatment of presbyopia
EP3826652A4 (en) Hepato-biliary-pancreatic tissues and methods of making same
EP3601460A4 (en) Polishing compositions and methods of use thereof
EP3833340A4 (en) Compositions and methods for treatment of presbyopia
EP3768315A4 (en) Fc variant compositions and methods of use thereof
EP3836944A4 (en) Leucine zipper-based compositions and methods of use
EP4034605A4 (en) Polishing compositions and methods of use thereof
EP3761989A4 (en) Imidazodiazepinediones and methods of use thereof
EP4045226A4 (en) Polishing compositions and methods of use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20210329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20220602BHEP

Ipc: A61K 9/107 20060101ALI20220602BHEP

Ipc: A61K 31/436 20060101ALI20220602BHEP

Ipc: A61K 31/56 20060101ALI20220602BHEP

Ipc: A61K 31/4725 20060101ALI20220602BHEP

Ipc: A61K 38/13 20060101ALI20220602BHEP

Ipc: A61K 31/498 20060101ALI20220602BHEP

Ipc: A61K 31/137 20060101ALI20220602BHEP

Ipc: A61K 47/32 20060101ALI20220602BHEP

Ipc: A61K 47/18 20170101ALI20220602BHEP

Ipc: A61K 47/12 20060101ALI20220602BHEP

Ipc: A61K 47/10 20170101ALI20220602BHEP

Ipc: A61K 47/26 20060101ALI20220602BHEP

Ipc: A61K 47/44 20170101ALI20220602BHEP

Ipc: A61K 31/573 20060101ALI20220602BHEP

Ipc: A61K 31/407 20060101ALI20220602BHEP

Ipc: A61K 9/08 20060101ALI20220602BHEP

Ipc: A61K 9/00 20060101ALI20220602BHEP

Ipc: A61K 31/417 20060101AFI20220602BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20220913

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20220907BHEP

Ipc: A61K 9/107 20060101ALI20220907BHEP

Ipc: A61K 31/436 20060101ALI20220907BHEP

Ipc: A61K 31/56 20060101ALI20220907BHEP

Ipc: A61K 31/4725 20060101ALI20220907BHEP

Ipc: A61K 38/13 20060101ALI20220907BHEP

Ipc: A61K 31/498 20060101ALI20220907BHEP

Ipc: A61K 31/137 20060101ALI20220907BHEP

Ipc: A61K 47/32 20060101ALI20220907BHEP

Ipc: A61K 47/18 20170101ALI20220907BHEP

Ipc: A61K 47/12 20060101ALI20220907BHEP

Ipc: A61K 47/10 20170101ALI20220907BHEP

Ipc: A61K 47/26 20060101ALI20220907BHEP

Ipc: A61K 47/44 20170101ALI20220907BHEP

Ipc: A61K 31/573 20060101ALI20220907BHEP

Ipc: A61K 31/407 20060101ALI20220907BHEP

Ipc: A61K 9/08 20060101ALI20220907BHEP

Ipc: A61K 9/00 20060101ALI20220907BHEP

Ipc: A61K 31/417 20060101AFI20220907BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230412